美加墨世界杯官方网站
What we do
Improving people’s lives and health outcomes by focusing on areas of high unmet medical need, we are accelerating our momentum and rapidly boosting our pipeline to bring the full potential of our innovative medicines to patients.
美加墨世界杯官方网站 Learn more美加墨世界杯官方网站
Oncology
people die from cancer every year, making it a leading global killer
Rare Diseases
people globally are living with a rare disease, most of whom have no approved treatment
Neuroscience
people worldwide live with spasticity, yet access to treatment remains limited
Underserved Population
of rare diseases begin in childhood yet most go undiagnosed or untreated
Our strategy has been instrumental in making us a leader in our field. Our global presence, resources, expertise and strong track record commercializing our medicines are resulting in a real impact for people living with high unmet medical needs. We’re leveraging the full force of Ipsen’s infrastructure, innovation and passion to develop new therapies and valuable collaborations.
美加墨世界杯官方网站
Find out what’s been going on at Ipsen of late – with press releases, trending stories, events, and more.
16 May 2026
Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of…
15 May 2026
Late-breaking data from EASL reinforces IQIRVO’s impact on ALP reduction with fatigue and pruritus improvement…
14 May 2026
Ipsen unveils corabotase, a first-in-class recombinant neuroinhibitor, RNI?, at the SCALE Symposium
23 April 2026
Ipsen delivers strong sales in the first quarter of 2026 and confirms its full-year guidance
22 April 2026
Ojemda? approved in the European Union as the first targeted therapy in relapsed or refractory…
12 March 2026
Ipsen appoints Michelle C. Werner as EVP, President of North America
12 February 2026
Ipsen delivers strong results in 2025, driven by solid execution across all therapeutic areas, and…
30 January 2026
Ipsen expands pre-clinical pipeline in rare neurodegenerative diseases
27 February 2026
Ipsen receives positive CHMP opinion for Ojemda? for the treatment as monotherapy of children with…
13 January 2026
U.S. FDA grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in first line unfit Acute Myeloid…
美加墨世界杯官方网站
Ipsen focuses on three key therapeutic areas, leveraging all our resources to help patients with unmet medical needs.
Oncology
Ipsen has been working in oncology since 1986, and now has a portfolio that includes treatments for neuroendocrine tumor (NETs), and cancers of the kidney, liver, pancreas, thyroid, prostate and breast.
Rare Disease
Ninety-four percent of rare medical conditions still have no treatment. We are committed to finding treatments for extremely rare bone diseases and disorders, growth disorders, rare cancers, rare liver disease and rare neurogenetic disorders.
Neuroscience
Ipsen draws on 30 years of expertise in toxins and neuroscience research to support children and adults suffering from debilitating and degenerative neurological conditions.
